Navigation Links
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Date:9/7/2007

SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three clinical data abstracts about its oral chemotherapy treatment Xeloda have been accepted for presentation at the 2007 Breast Cancer Symposium in San Francisco, Sept. 7 and 8.

Two of the abstracts include data from the XeNA (Xeloda in NeoAdjuvant) trial, a study of Xeloda and docetaxel with or without Herceptin in patients with invasive breast cancer. The third presentation highlights findings that validate efficacy and cost benefits of Xeloda in breast cancer patients.

-- Poster No. A54, [General Poster Session A, Sept. 7, 12:00 - 12:45

p.m.], "Frequency of circulating tumor cells (CTCs) in an open-label

study of neoadjuvant capecitabine, docetaxel and trastuzumab (CDT)

combination therapy in patients with HER2+ breast cancer (BC)."

(Presenter: Stefan Gluck)

-- Poster No. 100, [General Poster Session C, Sept. 8, 7:00 - 8:00 a.m.],

"Distribution of p53 mutations by AmpliChip assay in patients receiving

neoadjuvant capecitabine (C) plus docetaxel (D) with or without

trastuzumab (T) for newly diagnosed breast cancer (BC)." (Presenter:

Nancy Patten)

-- Poster No. A41, [General Poster Session D, Sept. 8, 11:45 a.m. - 12:45

p.m.], "Capecitabine is associated with fewer adverse events than other

standard therapies in patients with breast cancer: a claims database

analysis." (Presenter: Hope Rugo, M.D.)

These studies affirm Roche's commitment to exploring the expanded use of Xeloda in combination with new therapies. Additionally, the data explore the potential of oral Xeloda to offer effective treatment with a lower incidence of adverse events compared with traditional intravenous chemotherapy.

About Xeloda

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill for
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
(Date:7/29/2014)... 2014 According to a new ... Fixation Devices Market - Global Forecast, Market Share, Size, ... orthopedic trauma fixation devices market is estimated at USD ... at a CAGR of 7.2% from 2014 to 2019, ... in 2020. Browse the Orthopedic Trauma Fixation ...
(Date:7/29/2014)... -- Research and Markets has announced the ... report to their offering. ... a medical device used to provide medication or assist ... cannot achieve adequate oxygen levels to maintain life. Patients ... and ARDS require the need of respiratory devices. The ...
Breaking Medicine Technology:Drew Crawford Announces Launch of PBM365 Media 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Global Respiratory Devices Market 2014-2018 2
... May 19 A meta-analysis of approximately ... The Lancet on May 1, 2010 ... phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme, are associated ... in magnitude to that with non-HDL cholesterol or systolic ...
... SAN FRANCISCO , May 19 ... trials evaluating Ferring Pharmaceuticals, LYSTEDA™ (tranexamic acid) tablets, a ... with cyclic heavy menstrual bleeding (HMB), were presented at ... Clinical Meeting in San Francisco , May ...
Cached Medicine Technology:Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 2Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 3Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 4Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 5Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 6
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip indicates ... new method was created for any sufferer who is looking ... , The author of the new program, Sarah Summer, says ... actually suffered from yeast infection, too. Actually, this is the ... for this problem. , The Natural Cure for ...
(Date:7/29/2014)... For numerous women from all over the world, finding ... being quite hard. Well, the author of the Make Him ... can help all these women. This is the formula that ... and attention every day. , Daily Gossip reveals in ... Alex Carter who published a unique eBook to detail it. ...
(Date:7/29/2014)... Recent international changes to the ... Nurse Call Systems to be considered medical devices. ... Nurse Call Systems to be clinically regulated, audited ... reduces clinical risks, and is good news for ... and Clinical Risk Committee actively pursuing corporate governance. ...
(Date:7/29/2014)... Daily Gossip reveals in its review that the Tinnitus Miracle ... eliminate all the symptoms associated to this condition. , ... such as mild hearing loss, as well as headaches. The ... gone forever. , The method will lead to a cure ... says that at the end of the treatment, sufferers will ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:"Make Him Desire You" Review Reveals Unique Formula to Make Men Feel a Special Kind of Love 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 3Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 4Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2
... ,Using the male chromosome as a marker, researchers studying ... have discovered that the body can actively reshape the ... that the heart cannot repair itself and the finding ... realization that the body works to repair a damaged ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... say they have discovered molecules in the body ... free radicals.With further research, the research could potentially ... Oxidative damage has been linked with ailments such ... and diabetes, cancer and Alzheimer’s disease. ...
... a steroid nasal spray may relieve seasonal ... Dr. Robert Naclerio and colleagues from University ... nasal spray, with loratadine(Claritin),a nonsedating antihistamine, for ... , Participants who used the inhaled ...
... way to slow down the respiration rate. Just by practising ... can be slowed down and thereby calm the heart rhythm. ... ritual in the Catholic Church - and the benefits may ... Cleavland, recorded breathing rates during normal talking and recitation of ...
... from asthma, particularly women, may have an increased risk ... years, researchers studied almost 100,000 patients who had been ... showed any signs of cancer at their initial assessment. ... asthma diagnosis until the last day of the three-decade ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: